

PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 54540

Title: Sodium-glucose cotransporter 2 inhibitors' mechanisms of action in heart failure

Reviewer's code: 02453249

Position: Peer Reviewer

Academic degree: FAHA, MD

Professional title: Associate Professor

Reviewer's Country/Territory: Italy

Author's Country/Territory: Croatia

Manuscript submission date: 2020-02-17

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-02-18 07:36

Reviewer performed review: 2020-02-24 11:35

Review time: 6 Days and 3 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

The Authors aimed to discuss the proposed mechanisms of SGLT2 inhibitors in slowing the evolution of heart failure. The paper is very interesting. However, at least a table describing the quoted trials and a figure depicting the most plausible and accepted mechanisms would increase the value of the paper. There are also several issues regarding the effect of SGLT2 inhibitors and prevention of HF events that should be mentioned. In particular, as additional data are required to clarify the relative effect of SGLT2 inhibitors according to LVEF and according to disease severity, the Authors should report ongoing HF outcome studies addressing existing evidence gaps across a range of EF values and clinical status. If recent International guidelines include this drug for heart failure treatment should be reported.